GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, will effect a 1-for-24 reverse stock split of its common stock, the company announced. The move is aimed at regaining compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The split was approved by stockholders on October 27, 2026, and becomes effective at 12:01 a.m. ET on November 11, 2026.
Under the split, every 24 issued and outstanding shares will automatically convert into one share, without any change in par value. The total number of outstanding shares will drop from 12,209,871 to approximately 508,745. The stock will continue to trade under the symbol “GOVX” on a split-adjusted basis at the market open on the effective date, with a new CUSIP number, 373678 804. Each stockholder’s percentage ownership and proportional voting power will remain unchanged, except for minor adjustments from rounding fractional shares to the nearest whole number. The rights and privileges of common stockholders will be substantially unaffected.
The reverse split matters because failing to meet Nasdaq’s minimum bid price can lead to delisting, which would reduce liquidity, limit access to capital, and potentially harm investor confidence. For a clinical-stage company like GeoVax, maintaining a Nasdaq listing is important for raising the funds needed to advance its pipeline. GeoVax’s priority program is GEO-MVA, a Modified Vaccinia Ankara–based vaccine targeting mpox and smallpox, advancing under an expedited regulatory pathway with plans to initiate a pivotal Phase 3 trial in late 2026. In oncology, the company is developing Gedeptin®, a gene-directed enzyme prodrug therapy designed to enhance immune checkpoint inhibitor activity, which has completed a multicenter Phase 1/2 trial in advanced head and neck cancer. The split itself does not change the company’s underlying business or the value of stockholders’ proportional stakes, but it is a necessary step to preserve the listing that supports those development efforts.
Investors should note that while the split mechanically raises the per-share price, it does not guarantee that the stock will remain above $1.00, and the company may need to demonstrate sustained compliance. GeoVax maintains a global intellectual property portfolio supporting its infectious disease and oncology programs and continues to evaluate strategic partnerships and funding opportunities. More information about the company is available at www.geovax.com. The announcement was distributed via NEWMEDIAWIRE.
